CSIMarket
 


Abbott Laboratories  (ABT)
Other Ticker:  
 
 

ABT's Capital Expenditures Growth by Quarter and Year

Abbott Laboratories's Capital Expenditures results by quarter and year




ABT Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 679.00 434.00 467.00
III Quarter September - 496.00 401.00 354.00
II Quarter June - 642.00 468.00 298.00
I Quarter March 397.00 360.00 335.00 275.00
FY   397.00 2,177.00 1,638.00 1,394.00



ABT Capital Expenditures first quarter 2021 Y/Y Growth Comment
Abbott Laboratories reported Capital Expenditures increase of 10.28% year on year in the first quarter, to $ 397.00 millions, this is lower than Abbott Laboratories's recent average Capital Expenditures increase of 19.25%.

Looking into first quarter results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Capital Expenditures growth. While Abbott Laboratories' s Capital Expenditures growth of 10.28% ranks overall at the positon no. 411 in the first quarter.




ABT Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 56.45 % -7.07 % 35.36 %
III Quarter September - 23.69 % 13.28 % 34.6 %
II Quarter June - 37.18 % 57.05 % 16.86 %
I Quarter March 10.28 % 7.46 % 21.82 % 1.1 %
FY   - 32.91 % 17.5 % 22.82 %

Financial Statements
Abbott Laboratories's first quarter 2021 Capital Expenditures $ 397.00 millions ABT's Income Statement
Abbott Laboratories's first quarter 2020 Capital Expenditures $ 360.00 millions Quarterly ABT's Income Statement
New: More ABT's historic Capital Expenditures Growth >>


ABT Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 36.9 % 8.23 % 31.92 %
III Quarter September - -22.74 % -14.32 % 18.79 %
II Quarter June - 78.33 % 39.7 % 8.36 %
I Quarter March -41.53 % -17.05 % -28.27 % -20.29 %
FY (Year on Year)   - 32.91 % 17.5 % 22.82 %




Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #71
Overall #411

Capital Expenditures Y/Y Growth Statistics
High Average Low
736.03 % 19.25 % -17.16 %
(Dec. 31. 2009)   (Sep. 30, 2013)
Capital Expenditures first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #71
Overall #411
Capital Expenditures Y/Y Growth Statistics
High Average Low
736.03 % 19.25 % -17.16 %
(Dec. 31. 2009)   (Sep. 30, 2013)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Abbott Laboratories's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
111.57 % 6.8 % -100 %
(June 30. 2010)  


ABT's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Abbott Laboratories realized fall in Capital Expenditures from the forth quarter by -41.53% to $ 397.00 millions, from $ 679.00 millions released in the previous reporting period.

If you evaluate recent shortcoming at the I. Quarter, you must assume, that commonly I. Quarter performance appear to be sluggish relative to the quarter before, María José Gutiérrez, an industry consultant situated in Barcelona said.

Within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 829.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #125
Overall #829
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #34
Healthcare Sector #125
Overall #829
Capital Expenditures Q/Q Growth Statistics
High Average Low
111.57 % 6.8 % -100 %
(June 30. 2010)  


ABT's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2021 Abbott Laboratories reported fall in Capital Expenditures sequentially by -41.53% to $ 397.00 millions, from $ 679.00 millions achived a quarter before.

This is not huge issue, as Capital Expenditures generally gravitate to plunge in this quarter María José Gutiérrez, an industry consultant situated in Barcelona noted.

Within Major Pharmaceutical Preparations industry 33 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Abbott Laboratories's Capital Expenditures growth quarter on quarter, overall rank is 829.


Abbott Laboratories's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Capital Expenditures 12 Months Ending $ 2,214.00 $ 2,177.00 $ 1,932.00 $ 1,837.00 $ 1,663.00
Y / Y Capital Expenditures Growth (TTM) 33.13 % 32.91 % 15.62 % 13.12 % 14.37 %
Year on Year Capital Expenditures Growth Overall Ranking # 374 # 653 # 911 # 1119 # 1228
Seqeuential Capital Expenditures Change (TTM) 1.7 % 12.68 % 5.17 % 10.46 % 1.53 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 411 # 209 # 857 # 612 # 846




Cumulative Capital Expenditures growth Comment
Abbott Laboratories saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 33.13% year on year, to $ 2,214 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Capital Expenditures growth was higher than company's average 25.62% and higher than 32.91% growth in Dec 31 2020.
But from the previous reporting period increase was slower at 1.7 % from $2177 millions achieved in twelve months ending a quarter before María José Gutiérrez added on.
It appears to be slowdown developing, more obvious as we look at When you average Q/Q TTM Capital Expenditures increase that is higher at 19.25%.
The momentum was even higher from twelve months ended Dec 31 2020 showed at 1.7 % rise from $2177 millions in twelve months ending a quarter Dec 31 2020.

In the Healthcare sector 93 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 374, from total ranking in previous quarter at 653.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
736.03 %
19.25 %
-17.16 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 94
Overall # 373

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
697.91 %
25.62 %
-36.22 %
(Sep. 30, 2010)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 71
S&P 500 # 411
Cumulative Capital Expenditures growth Comment
Abbott Laboratories saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 33.13% year on year, to $ 2,214 millions if the fiscal year would have ended in Mar 31 2021.
Abbott Laboratories's trailing twelve months Capital Expenditures growth was higher than company's average 25.62% and higher than 32.91% growth in Dec 31 2020.
But from the previous reporting period increase was less at 1.7 % from $2177 millions achieved in the period from Dec 31 2020 to Mar 31 2020.
There is stagnation happening, more evident if you pay attention to the When you typical Q/Q TTM historic rise what is stronger at19.25%.
The momentum was even stronger from the previous reporting period clinched at 1.7 % increase from $2177 millions in twelve months ending a quarter before.

In the Healthcare sector 93 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 374, from total ranking in previous quarter at 653.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
736.03 %
19.25 %
-17.16 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 94
Overall # 373

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
697.91 %
25.62 %
-36.22 %
(Sep. 30, 2010)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 71
S&P 500 # 411




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ABT's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ABT's Competitors
Capital Expenditures Growth for Abbott Laboratories's Suppliers
Capital Expenditures Growth for ABT's Customers

You may also want to know
ABT's Annual Growth Rates ABT's Profitability Ratios ABT's Asset Turnover Ratio ABT's Dividend Growth
ABT's Roe ABT's Valuation Ratios ABT's Financial Strength Ratios ABT's Dividend Payout Ratio
ABT's Roa ABT's Inventory Turnover Ratio ABT's Growth Rates ABT's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2021
Protara Therapeutics Inc 17.41%$ 17.408 millions
Teva Pharmaceutical Industries Ltd17.19%$ 17.188 millions
Dentsply Sirona Inc 17.19%$ 17.188 millions
Medpace Holdings inc 17.01%$ 17.011 millions
Amgen Inc 16.90%$ 16.901 millions
Ultragenyx Pharmaceutical Inc 16.44%$ 16.444 millions
Eli Lilly And Company16.26%$ 16.260 millions
Owens and Minor Inc 15.93%$ 15.929 millions
Establishment Labs Holdings Inc 15.70%$ 15.701 millions
Acadia Pharmaceuticals Inc 15.20%$ 15.203 millions
Merck and Co Inc 15.01%$ 15.010 millions
Chembio Diagnostics Inc 14.92%$ 14.922 millions
Bio techne Corp14.22%$ 14.221 millions
Becton Dickinson And Company13.96%$ 13.964 millions
Ptc Therapeutics inc 13.77%$ 13.771 millions
Amedisys Inc12.83%$ 12.831 millions
Apellis Pharmaceuticals inc 11.26%$ 11.264 millions
Abbott Laboratories10.28%$ 10.278 millions
Conmed Corporation10.05%$ 10.053 millions
Charles River Laboratories International inc 8.98%$ 8.977 millions
Hill rom Holdings Inc 8.72%$ 8.716 millions
Healthcare Services Group Inc 7.87%$ 7.868 millions
Aptose Biosciences Inc 6.25%$ 6.250 millions
Merus N v 6.08%$ 6.081 millions
Community Health Systems Inc 6.06%$ 6.061 millions
Hologic Inc6.04%$ 6.044 millions
Iqvia Holdings Inc 5.67%$ 5.674 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CCMP's Profile

Stock Price

CCMP's Financials

Business Description

Fundamentals

Charts & Quotes

CCMP's News

Suppliers

CCMP's Competitors

Customers & Markets

Economic Indicators

CCMP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071